Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis.
Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis.
复制标题
DOI：
10.3389/fonc.2023.1245650
复制
发表时间：
2023
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
卡培他滨辅助治疗早期三阴性乳腺癌的疗效和安全性尚不明确。进行了一项荟萃分析，以阐明基于卡培他滨的方案是否可以改善早期三阴性乳腺癌（TNBC）的生存率。本研究检索了Medline、Embase、科克伦图书馆、Web of Science和ClinicalTrials.gov会议记录，截止日期为2023年9月。评估无病生存期（DFS）、总生存期（OS）和3-4级不良事件（AE）。汇总提取或计算的风险比（HR）和比值比（OR）以及95%置信区间（CI）。在12项随机对照试验（RCT）中，5，390例受试者中，以卡培他滨为基础的方案在DFS（HR = 0.81，95% CI：0.73-0.90; P <.001）和OS（HR = 0.75，95% CI：0.65-0.87; P <.001）方面显示出显著优势。DFS亚组分析显示，淋巴结阴性（HR = 0.68; 95% CI：0.50-0.92; P = 0.006）和卡培他滨持续时间不少于6个周期（HR = 0.73; 95% CI：0.62-0.86; P <0.001）患者的结果相似。观察到添加组（HR = 0.77，95% CI：0.68-0.87; P <0.001）和辅助治疗组（HR = 0.79，95% CI：0.70-0.89; P <0.001）的DFS改善。至于安全性特征，卡培他滨与更频繁的口腔炎相关（OR = 5.05，95% CI：1.45-17.65，P = .011），腹泻（OR = 6.11，95%CI：2.12-17.56; P =.001）和手足综合征（OR = 31.82，95%CI：3.23-313.65，P = .003）。基于卡培他滨的辅助化疗提供了优于早期TNBC的上级DFS和OS。在选定的淋巴结阴性患者中证实了DFS的益处，并证明了卡培他滨的添加和持续时间的延长。
The efficacy and safety of adjuvant capecitabine in early-stage triple-negative breast cancer remains undefined. A meta-analysis was conducted to elucidate whether capecitabine-based regimens could improve survival in early-stage triple-negative breast cancer (TNBC). The current study searched Medline, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov proceedings up to 2023.9. Disease-free survival (DFS), overall survival (OS), and grade 3–4 adverse events (AEs) were assessed. Extracted or calculated hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled. The capecitabine-based regimens showed significant advantages in DFS (HR = 0.81, 95% CI: 0.73–0.90; P <.001) and OS (HR = 0.75, 95% CI: 0.65–0.87; P <.001) from 12 randomized controlled trials (RCTs) with 5,390 unselected participants. Subgroup analysis of DFS showed analogous results derived from patients with lymph node negative (HR = 0.68, 95% CI: 0.50–0.92; P = .006) and capecitabine duration no less than six cycles (HR = 0.73; 95% CI: 0.62-0.86; P <.001). Improvement of DFS in the addition group (HR = 0.77, 95% CI: 0.68–0.87; P <.001) and adjuvant setting (HR = 0.79, 95% CI: 0.70–0.89; P <.001) was observed. As to safety profile, capecitabine was associated with more frequent stomatitis (OR = 5.05, 95% CI: 1.45–17.65, P = .011), diarrhea (OR = 6.11, 95% CI: 2.12–17.56; P =.001), and hand–foot syndrome (OR = 31.82, 95% CI: 3.23–313.65, P = .003). Adjuvant capecitabine-based chemotherapy provided superior DFS and OS to early-stage TNBC. The benefits to DFS in selected patients with lymph node negative and the addition and extended duration of capecitabine were demonstrated.
登录
查看更多内容
早期三阴性乳腺癌患者的辅助卡皮替滨化学疗法的益处和同源重组缺乏症。
影响因子：
8.8
作者：
de Boo, Leonora W.;Jozwiak, Katarzyna;Joensuu, Heikki;Lindman, Henrik;Lauttia, Susanna;Opdam, Mark;van Steenis, Charlaine;Brugman, Wim;Kluin, Roelof J. C.;Schouten, Philip C.;Kok, Marleen;Nederlof, Petra M.;Hauptmann, Michael;Linn, Sabine C.
通讯作者：
Linn, Sabine C.
影响因子：
3.8
作者：
Twelves, Chris;Cortes, Javier;Vahdat, Linda;Olivo, Martin;He, Yi;Kaufman, Peter A.;Awada, Ahmad
通讯作者：
Awada, Ahmad
DOI：
10.1158/1078-0432.ccr-22-2191
发表时间：
2023-01-17
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Asleh K;Lluch A;Goytain A;Barrios C;Wang XQ;Torrecillas L;Gao D;Ruiz-Borrego M;Leung S;Bines J;Guerrero-Zotano Á;García-Sáenz JÁ;Cejalvo JM;Herranz J;Torres R;Haba-Rodriguez J;Ayala F;Gómez H;Rojo F;Nielsen TO;Martin M
通讯作者：
Martin M
影响因子：
3.7
作者：
Moher D;Shamseer L;Clarke M;Ghersi D;Liberati A;Petticrew M;Shekelle P;Stewart LA;PRISMA-P Group
通讯作者：
PRISMA-P Group
影响因子：
45.3
作者：
Muss, Hyman B.;Polley, Mei-Yin C.;Carey, Lisa
通讯作者：
Carey, Lisa